See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new pre-exposure prophylaxis (PrEP) drug has shown promise as a ...

It’s possible to produce a generic version of lenacapavir, a twice-yearly antiretroviral injection that both prevents and treats HIV, for as little as $25 per patient per year, according to a study ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Gilead's CEO earlier this year ...

From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. And, for the twice-yearly pre-exposure prophylaxis (PrEP) medication—which Gilead ...

Preexposure prophylaxis, known as PrEP, reduces the risk of new HIV infections through sex by 99% and among injectable drug users by at least 74%, according to the Centers for Disease Control and ...

When Dr. Sharon Nachman treats teenagers or young adults, she often asks about their sexual health and whether they would consider a medication that can vastly improve the chances of avoiding an HIV ...

Bisexual men encounter unique sexual health risks due to their sexual relationships with both men and women. This dual-risk exposure can sometimes lead to higher rates of STIs, including HIV, herpes, ...

Alexis Perkins thought her OB-GYN's office in Atlanta would be just the place to get a prescription for the type of drug that reduces a person's risk of contracting HIV. But during a recent visit, the ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

Add Yahoo as a preferred source to see more of our stories on Google. It’s been over a decade since the Food and Drug Administration first approved a medication to prevent HIV. But the Centers for ...